| |
Tuesday, February 7, 2023 | 11am ET / 8am PT This session will focus upon understanding your knowns and unknowns, best practices for mitigating risk, and addressing the specific drug supply challenges commonly associated with complex trial designs. Register now.
|
|
Today's Big NewsFeb 3, 2023 |
|
Thursday, Feb 16, 2023 | 2:00pm ET During this session, NetApp will explore how data is leveraged in Life Sciences to create a data fabric strategy that’s aligned to your business. This includes how to detailing each cycle of the data foundation for data governance and quality, data accessibility, data platforms, data as a service, data as a business, predictive intelligence, optimizing how solutions are managed across the data lifecycle, and more. Register now.
|
|
| By Max Bayer,Fraiser Kansteiner Johnson and Johnson's pharmaceutical unit Janssen is undergoing a seismic overhaul, folding its infectious disease team with the vaccines unit and discontinuing numerous programs in the process. As a result, the company expects to lay off employees in several countries. |
|
|
|
By James Waldron Could we see Sanofi give up on cancer? Not according to Paul Hudson, although the CEO admitted that after some struggles with its headline candidates, the French pharma might seek solace earlier in its pipeline. |
By Paige Minemyer Express Scripts is kicking off 2023 with a new leader at the helm. |
By Andrea Park A new tool from Siemens Healthineers’ Varian Medical Systems allows doctors to capture images of tumors in mere seconds and calculate changes in both the tumor and nearby organs, then use those data to adapt a patient’s treatment over time. |
|
Tuesday, Feb 28, 2023 | 11:00am ET The heavy lifting for the pharmaceutical industry to comply with the November 2023 DSCSA go-live date is still ongoing. One item now finalized is to ensure that the required data exchange through the supply chain is only done with trusted, authorized, and registered trading partners. Join us for this discussion to stay up-to-date on this important legislation and be prepared for compliance. Register now.
|
|
By Heather Landi Health tech unicorn Aledade recently announced that it made the strategic decision to become a public benefit corporation. The company is among just a handful of healthcare companies that are structured this way. What does it mean, and should others join them? |
By Zoey Becker Even as sales of Gilead Sciences' COVID-19 drug Veklury slow along with pandemic hospitalizations, the company was able to celebrate growth for its core offerings in 2022. |
By Andrea Park Half a decade after it began, an intellectual property case between Boston Scientific and TissueGen has finally reached a verdict. |
By Gabrielle Masson 4D Molecular Therapeutics is on shaky ground as its Fabry disease gene therapy program, dubbed 4D-310, has been hit with an FDA clinical hold. |
By Kevin Dunleavy Regeneron anticipates an August launch for its new longer-lasting version of Eylea as it tries to fend off Roche's Vabysmo. Eylea delivered an 8% increase in sales last year, despite a 3% drop in the fourth quarter. |
By Conor Hale Abbott scored two device approvals for its cardiac ablation catheters for treating abnormal heart rhythms—one on each side of the pond. |
By Dave Muoio Over 2.8 million people's protected information was compromised in a 2016 cyberattack. Upon investigation, the government said that Banner Health could have done more to prepare and respond. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
Fierce podcastsDon't miss an episode |
| | In this week's episode of "Podnosis," we discuss post-pandemic hospital financing and what leaders will need to focus on this year and beyond. We also talk about the importance of value-based care and how to account for equitable care. |
|
|---|
|
|
|
The global demand for biologics is projected to increase considerably by 2030, but the challenges, risks, and costs are also growing. For pharma companies looking to bring a new biologic to market, meeting clinical trial milestones can be difficult. To access important insights, download this executive summary now.
|
|
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
